Casdin Capital, LLC Q4 2016 Filing

Filed February 14, 2017

Portfolio Value

$121.1B

Holdings

25

Report Date

Q4 2016

Filing Type

13F-HR

All Holdings (25 positions)

#StockSharesValue% PortfolioType
1
SG7SAGE THERAPEUTICS INC
259,500$13.3B10.94%
2
LOXO ONCOLOGY INC
360,000$11.6B9.55%
3
AGIOAGIOS PHARMACEUTICALS INC
240,500$10.0B8.29%
4
FOUNDATION MEDICINE INC
546,000$9.7B7.98%
5
EVHEVOLENT HEALTH INC
555,000$8.2B6.78%
6
2L9BLUEPRINT MEDICINES CORP
244,500$6.9B5.66%
7
SPARK THERAPEUTICS INC
128,500$6.4B5.30%
8
GENMARK DIAGNOSTICS INC
510,000$6.2B5.16%
9
BLUEBIRD BIO INC
82,500$5.1B4.20%
10
VYGRVOYAGER THERAPEUTICS INC
385,000$4.9B4.05%
11
GBTUSDGLOBAL BLOOD THERAPEUTICS IN
304,000$4.4B3.63%
12
KITE PHARMA INC
94,000$4.2B3.48%
13
MYOKARDIA INC
265,000$3.4B2.83%
14
EPIZYME INC
275,000$3.3B2.75%
15
ILMNILLUMINA INC
25,000$3.2B2.64%
16
ALNYALNYLAM PHARMACEUTICALS INC
85,000$3.2B2.63%
17
CERNCHFCERNER CORP
65,000$3.1B2.54%
18
MDRXALLSCRIPTS HEALTHCARE SOLUTN
280,000$2.9B2.36%
19
AMYRIS INC
3,425,000$2.5B2.06%
20
SYROS PHARMACEUTICALS INC
182,141$2.2B1.83%
21
AEVI GENOMIC MEDICINE INC
375,000$1.9B1.60%
22
CTMXCYTOMX THERAPEUTICS INC
127,500$1.4B1.16%
23
XLRNACCELERON PHARMA INC
45,000$1.1B0.95%
24
EDITEDITAS MEDICINE INC
65,000$1.1B0.87%
25
GILDGILEAD SCIENCES INC
12,500$895.0M0.74%